SCI & TECH● LOW3h ago · Oct 2, 2026, 3:20 PM
Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s
CNBC · global
Eli Lilly and Novo are developing new amylin drugs that serve as another biological lever to pull in treating obesity and diabetes.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Sci & Tech
SCI & TECH17m agoAI Beats Top Human Stratego Players for the First TimeHuman ProgressSCI & TECH1h agoThrowing cinnamon powder on mother-in-law's tongue plant soil: what it's for and why gardeners recommend itClarínSCI & TECH1h agoThe AI revolution is likely to drive up your electricity bill. Here's why.CBS NewsSCI & TECH1h agoPsychology says that people who rewrite their entire to-do list every morning are not wasting time: writing tasks unloads them from working memory, and rewriting is what calms annoying thoughtsClarín